Brian P Hobbs

List of Publications by Year in Descending Order

60 papers	**1,374** citations	**20** h-index	**36** g-index
66 ext. papers	**1,991** ext. citations	**4.5** avg, IF	**4.9** L-index

#	Paper	IF	Citations
60	Calibrated dynamic borrowing using capping priors.. *Journal of Biopharmaceutical Statistics*, **2022**, 1-16	1.3	
59	Bayesian basket trial design with false-discovery rate control.. *Clinical Trials*, **2022**, 17407745211073624	2.2	0
58	Optimal Sequential Predictive Probability Designs for Early-Phase Oncology Expansion Cohorts.. *JCO Precision Oncology*, **2022**, 6, e2100390	3.6	0
57	Basket Trials: Review of Current Practice and Innovations for Future Trials.. *Journal of Clinical Oncology*, **2022**, JCO2102285	2.2	0
56	Identifying Individualized Risk Profiles for Radiotherapy-Induced Lymphopenia Among Patients With Esophageal Cancer Using Machine Learning. *JCO Clinical Cancer Informatics*, **2021**, 5, 1044-1053	5.2	1
55	Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy. *Med*, **2021**, 2, 423-434	31.7	17
54	Comparing phase 3 go decisions (Ph3-GO) between single arm trials with real-world external control (SAT+rwEC) versus randomized phase 2 trials (rPh2).. *Journal of Clinical Oncology*, **2021**, 39, e13564-e13564	2.2	
53	Moving Beyond 3+3: The Future of Clinical Trial Design. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2021**, 41, e133-e144	7.1	3
52	Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. *Lancet Respiratory Medicine,the*, **2021**, 9, 467-475	35.1	72
51	Statistical design considerations for trials that study multiple indications. *Statistical Methods in Medical Research*, **2021**, 30, 785-798	2.3	3
50	Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival **2021**, 9,		28
49	A Bayesian nonparametric model for textural pattern heterogeneity. *Journal of the Royal Statistical Society Series C: Applied Statistics*, **2021**, 70, 459-480	1.5	1
48	A survival mediation model with Bayesian model averaging. *Statistical Methods in Medical Research*, **2021**, 30, 2413-2427	2.3	0
47	Current status and application of proton therapy for esophageal cancer. *Radiotherapy and Oncology*, **2021**, 164, 27-36	5.3	1
46	Outcomes with Partial Breast Irradiation vs. Whole Breast Irradiation: a Meta-Analysis. *Annals of Surgical Oncology*, **2021**, 28, 4985-4994	3.1	5
45	Histology-agnostic drug development - considering issues beyond the tissue. *Nature Reviews Clinical Oncology*, **2020**, 17, 555-568	19.4	25
44	Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. *Journal of Clinical Oncology*, **2020**, 38, 1569-1579	2.2	70

#	Citation	IF	Cites
43	Elucidating Determinants of Survival Disparities Among a Real-world Cohort of Metastatic Breast Cancer Patients: A National Cancer Database Analysis. *Clinical Breast Cancer*, **2020**, 20, e625-e650	3	1
42	Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC. *Journal of Thoracic Oncology*, **2020**, 15, 101-109	8.9	14
41	The Diminishing Impact of Margin Definitions and Width on Local Recurrence Rates following Breast-Conserving Therapy for Early-Stage Invasive Cancer: A Meta-Analysis. *Annals of Surgical Oncology*, **2020**, 27, 4628-4636	3.1	1
40	Comparing Radiation Modalities with Trimodality Therapy Using Total Toxicity Burden. *International Journal of Radiation Oncology Biology Physics*, **2020**, 107, 1001-1005	4	0
39	A functional model for classifying metastatic lesions integrating scans and biomarkers. *Statistical Methods in Medical Research*, **2020**, 29, 137-150	2.3	1
38	Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. *Lancet Oncology, The*, **2019**, 20, 1386-1394	21.7	50
37	A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy **2019**, 7, 127		13
36	Time to initial cancer treatment in the United States and association with survival over time: An observational study. *PLoS ONE*, **2019**, 14, e0213209	3.7	71
35	Estimating mean local posterior predictive benefit for biomarker-guided treatment strategies. *Statistical Methods in Medical Research*, **2019**, 28, 2820-2833	2.3	
34	Phase II study of Dovitinib in recurrent glioblastoma. *Journal of Neuro-Oncology*, **2019**, 144, 359-368	4.8	16
33	How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS. *Blood*, **2019**, 134, 1716-1716	21.7	1
32	The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy. *Blood*, **2019**, 134, 16-16	2.2	2
31	Disparities in treatment patterns and overall survival (OS) in hormone receptor-positive HER2+ metastatic breast cancer (MBC): A National Cancer Database Analysis.. *Journal of Clinical Oncology*, **2019**, 37, 1032-1032	2.2	1
30	Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies. *Blood*, **2019**, 134, 3433-3433	2.2	
29	Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?. *Blood*, **2019**, 134, 381-381	2.2	0
28	A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy. *Blood*, **2019**, 134, 2595-2595	2.2	
27	Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients. *Blood*, **2019**, 134, 3836-3836	2.2	
26	Bayesian personalized treatment selection strategies that integrate predictive with prognostic determinants. *Biometrical Journal*, **2019**, 61, 902-917	1.5	4

25	Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis. *Scientific Reports*, **2019**, 9, 18126	4.9	13
24	Basket Designs: Statistical Considerations for Oncology Trials.. *JCO Precision Oncology*, **2019**, 3, 1-9	3.6	2
23	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. *Journal of the National Cancer Institute*, **2019**, 111, 118-128	9.7	33
22	Bayesian hierarchical modeling based on multisource exchangeability. *Biostatistics*, **2018**, 19, 169-184	3.7	25
21	A multi-source adaptive platform design for testing sequential combinatorial therapeutic strategies. *Biometrics*, **2018**, 74, 1082-1094	1.8	20
20	Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. *Scientific Reports*, **2018**, 8, 1922	4.9	70
19	Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. *Radiotherapy and Oncology*, **2018**, 128, 154-160	5.3	68
18	Controlled multi-arm platform design using predictive probability. *Statistical Methods in Medical Research*, **2018**, 27, 65-78	2.3	46
17	Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. *Statistical Methods in Medical Research*, **2018**, 27, 2093-2113	2.3	3
16	Bayesian basket trial design with exchangeability monitoring. *Statistics in Medicine*, **2018**, 37, 3557-3572	2.3	41
15	Spatial Bayesian modeling of GLCM with application to malignant lesion characterization. *Journal of Applied Statistics*, **2018**, 46, 230-246	1	8
14	Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay. *Blood*, **2018**, 132, 4806-4806	2.2	1
13	Lymphocyte-Sparing Effect of Proton Therapy in Patients with Esophageal Cancer Treated with Definitive Chemoradiation. *International Journal of Particle Therapy*, **2018**, 4, 23-32	1.5	40
12	Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia. *Blood*, **2018**, 132, 1527-1527	2.2	
11	Web-based statistical tools for the analysis and design of clinical trials that incorporate historical controls. *Computational Statistics and Data Analysis*, **2018**, 127, 50-68	1.6	7
10	Contrast-associated acute kidney injury in the critically ill: systematic review and Bayesian meta-analysis. *Intensive Care Medicine*, **2017**, 43, 785-794	14.5	34
9	Definitive Chemoradiation Therapy for Esophageal Cancer in the Elderly: Clinical Outcomes for Patients Exceeding 80 Years Old. *International Journal of Radiation Oncology Biology Physics*, **2017**, 98, 811-819	4	29
8	Bayesian predictive modeling for genomic based personalized treatment selection. *Biometrics*, **2016**, 72, 575-83	1.8	9

LIST OF PUBLICATIONS

7	Bayesian Group Sequential Clinical Trial Design using Total Toxicity Burden and Progression-Free Survival. *Journal of the Royal Statistical Society Series C: Applied Statistics*, **2016**, 65, 273-297	1.5	21
6	COMBINING NONEXCHANGEABLE FUNCTIONAL OR SURVIVAL DATA SOURCES IN ONCOLOGY USING GENERALIZED MIXTURE COMMENSURATE PRIORS. *Annals of Applied Statistics*, **2015**, 9, 1549-1570	2.1	9
5	Predictive classification of correlated targets with application to detection of metastatic cancer using functional CT imaging. *Biometrics*, **2015**, 71, 792-802	1.8	6
4	Use of historical control data for assessing treatment effects in clinical trials. *Pharmaceutical Statistics*, **2014**, 13, 41-54	1	218
3	Metastases to the liver from neuroendocrine tumors: effect of duration of scan acquisition on CT perfusion values. *Radiology*, **2013**, 269, 758-67	20.5	23
2	Adaptive adjustment of the randomization ratio using historical control data. *Clinical Trials*, **2013**, 10, 430-40	2.2	63
1	Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials. *Biometrics*, **2011**, 67, 1047-56	1.8	173